Twilight Litaka Pharma Limited
Regd. Office : B-22, 'H' BLOCK, MIDC PIMPRI, PUNE-411018

PART I

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH SEPTEMBER, 2012

(Rs.in Lac)

S No.	Particulars	Quarter Ended			Year to Date		Previous Year ended
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)
		30.09.2012	30.06.2012	30.09.2011	30.09.2012	30.09.2011	31.03.2012
1	a. Net Sales / Income From Operations	8995.17	16033.62	18065.15	25028.79	36421.14	72953.71
	b. Other Operating Income			-		-	
2	Expenditure						
	a Increase/decrease in stock in trade & WIP	304.38	49.78	6.88	354.16	-163.33	-281.24
	b Consumption of Raw material	4014.01	7717.23	12168.33	11731.24	25035.44	40055.87
	c Purchase of traded goods.	2982.13	4891.26	1577.12	7873.39	2934.41	16402.58
	d Employee cost	254.85	453.76	513.99	708.61	991.56	1982.39
	e Depreciation	132.63	135.96	144.80	268.59	249.09	510.25
	f Other expenditure	896.46	1067.99	1167.22	1964.45	2196.68	4661.34
	g Expenditure (a to f)	8584.46	14315.98	15578.34	22900.44	31243.85	63331.20
3	**Profit from Operations before Other Income, Interest and Exceptional Items (1-2)**	410.71	1717.64	2486.81	2128.35	5177.29	9622.51
4	Other Income	13.56	20.29	42.12	33.85	63.61	332.60
5	**Profit before Interest & Exceptional Items (3+4)**	424.27	1737.93	2528.93	2162.20	5240.90	9955.11
6	Interest	1006.68	1449.13	1198.72	2455.81	2182.33	4698.28
7	**Profit/(Loss) after Interest, but before Exceptional Items (5-6)**	(582.41)	288.80	1330.21	(293.61)	3058.57	5256.83
8	Exceptional Items	-	-	-	-	-	-
9	**Profit/(Loss) from Ordinary Activities before tax (7+8)**	(582.41)	288.80	1330.21	(293.61)	3058.57	5256.83
10	Tax Expenses	0.00	75.00	347.00	75.00	793.00	1360.00
11	**Net Profit/(Loss) from Ordinary Activities after tax (9-10)**	(582.41)	213.80	983.21	(368.61)	2265.57	3896.83
12	Extraordinary items (net of tax expense)	-	-	-	-	-	-
13	**Net Profit/(Loss) for the period**	(582.41)	213.80	983.21	(368.61)	2265.57	3896.83
14	Paid-up Equity Share Capital (Equity share of Rs.5/- each)	1239.06	1239.06	1239.06	1239.06	1239.06	1239.06
15	Reserve excluding revaluation reserves	19058.43	19640.84	17899.77	19058.43	17899.77	19427.04
16	Earning per share (EPS)						
	a. Basic and diluted EPS before extraordinary items for the period	(2.35)	*0.86	*3.85	(1.49)	*9.70	*16.19
	b. Basic and diluted EPS after extraordinary items for the period.	(2.35)	*0.86	*3.85	(1.49)	*9.70	*16.19
II	**INFORMATION FOR THE QUARTER AND SIX MONTHS ENDED 30.09.2012**						
A	**PARTICULARSOF SHAREHOLDING**						
1	Aggregate of non promoter shareholding						
	number of shares	23683261	23674261	22171810	23683261	22171810	23520796
	percentage of shareholding	95.57	95.53	89.47	95.57	89.47	94.91
2	Promoters and Promoters Group shareholding						
	a) Pledged / Encumbered						
	- Number of shares	796938	1011467	2126606	796938	2126606	1236247
	- Percentage of shares (as % to the total shareholding of promoters & promoters group)	72.58	91.37	81.50	72.58	81.50	98.07
	- Percentage of shares (as % to the total share capital of the Company)	3.22	4.08	8.58	3.22	8.58	4.99
	b) Non Encumbered						
	- Number of shares	301086	95557	482869.00	301086	482869.00	24242
	- Percentage of shares (as % to the total shareholding of promoters & promoters group)	27.42	8.63	18.50	27.42	18.50	1.93
	- Percentage of shares (as % to the total share capital of the Company)	1.21	0.39	1.95	1.21	1.95	0.10

B	INVESTOR COMPLAINTS	30.09.2012
	Pending at the beginning of the quarter	15
	Received during the quarter	2
	Disposed of during the quarter	17
	Remaining unresolved at the end of the quarter	Nil

* not annualised

Notes :

1] The above unaudited results were reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 12th November, 2012.

2] The Company is primarily engaged in Pharmaceutical formulations business, which in the context of Accounting Standard (AS17) "'Segment Reporting" is considered to be the only business segment.

3] The financial results for the quarter and half year ended on 30th September,2012 of the company are prepared on standalone basis.

4] The accounts for the year ending 31st March, 2012 is under finalisation and under audit. Hence Balance Sheet figures for 30th September 2012 are not provided.

5] During the period under review the Company's Bank accounts became NPA.Some of the banks have issued notices/initiated proceedings for recovery. Some of the creditors of the company have filed windig up petitions.

6] The above results were subject to Limited Review by the Statutory Auditors of the Company pursuant to Clause 41 of the Listing Agreement.

7] Previous year's figures have been regrouped and rearranged wherever necessary.

For TWILIGHT LITAKA PHARMA LIMITED

GOPAL RAMOURTI
Managing Director

TWILIGHT LITAKA PHARMA LTD. PUNE

Place : Pune
Date : 12/11/2012